Black Diamond Therapeutics, Inc.
BDTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001701541
No open-market purchases or sales by Black Diamond Therapeutics, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $64.9M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Black Diamond Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 95
- −6 vs. Q3 2021
- Shares held
- 23.2M
- −1.17M (−4.8%) vs. Q3 2021
- Total value
- $123.7M
- −$82.7M (−40.1%) vs. Q3 2021
- New holders
- 21
- 21 more added
- Sold out
- 27
- 28 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BDTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 96 | $64.9M |
| Q1 2026 | 104 | $82.0M |
| Q4 2025 | 104 | $92.0M |
| Q3 2025 | 91 | $147.0M |
| Q2 2025 | 94 | $95.8M |
| Q1 2025 | 85 | $63.0M |
| Q4 2024 | 88 | $102.5M |
| Q3 2024 | 96 | $211.9M |
| Q2 2024 | 90 | $217.9M |
| Q1 2024 | 88 | $199.9M |
| Q4 2023 | 76 | $107.1M |
| Q3 2023 | 73 | $106.8M |
| Q2 2023 | 74 | $209.2M |
| Q1 2023 | 50 | $40.6M |
| Q4 2022 | 59 | $37.9M |
| Q3 2022 | 69 | $36.3M |
| Q2 2022 | 74 | $52.9M |
| Q1 2022 | 87 | $63.5M |
| Q4 2021 | 95 | $123.7M |
| Q3 2021 | 101 | $206.3M |
| Q2 2021 | 102 | $309.6M |
| Q1 2021 | 113 | $705.5M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Black Diamond Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Swiss National Bank | 0 | $0 | 0.00% | −47,600−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −24,100−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −22,432−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −21,432−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −16,600−100.0% | Sold out |
| Virginia Retirement Systems Et Al | 0 | $0 | 0.00% | −10,800−100.0% | Sold out |
| Invesco Ltd. | 0 | $0 | 0.00% | −10,633−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −10,307−100.0% | Sold out |
| Great West Life Assurance Co | 0 | $0 | 0.00% | −879−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −830−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −728−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −590−100.0% | Sold out |
| MCF Advisors LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Liberty Wealth Management LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −302−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −298−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −178−100.0% | Sold out |
| Brewin Dolphin Ltd | 0 | $0 | 0.00% | −135−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −173−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −112−100.0% | Sold out |
| Harbour Investments, Inc. | 0 | $0 | 0.00% | −54−100.0% | Sold out |